XtalPi Inc. (2228.HK) has announced a significant new collaboration with China Pharmaceutical University (CPU), making its proprietary AI drug discovery platform accessible to the university’s faculty and students. Leveraging XtalPi’s expertise in AI-driven drug development and its successful track record in industrial applications, the platform’s first phase, featuring the PatSight drug patent analysis software, has been fully deployed. Subsequent phases will include tailored deployments for additional drug discovery scenarios, such as molecular design and efficacy evaluation. This partnership marks another milestone following the establishment of a joint research center between XtalPi and CPU, reinforcing their commitment to advancing intelligent and automated drug discovery infrastructure. Together, they aim to explore innovative models for integrating industry and academia, as well as science and education.
XtalPi’s AI drug discovery platform integrates cutting-edge technologies, including quantum physics, artificial intelligence, and cloud computing. In molecular drug design, the platform enables exploration of vast drug-like chemical spaces and screens for multiple drug properties. Researchers can virtually identify compounds with critical attributes—such as non-toxicity, solubility, and affinity—in significantly less time and at lower costs, dramatically enhancing R&D efficiency.
This collaboration provides unprecedented support for CPU’s faculty and students, empowering both research and education.
For research, the platform enables faculty to conduct in-depth studies in areas like compound library synthesis, molecular building block design, and reaction condition screening. Previously, large-scale, high-precision experiments were limited by manpower and traditional methods. Now, with XtalPi’s platform, research teams can design experiments, analyze data, and accelerate breakthroughs more efficiently.
For education, students gain hands-on access to industry-leading intelligent R&D tools, bridging classroom knowledge in pharmaceutical sciences with advanced AI technologies. This practical experience enhances their professional skills and prepares them for careers in intelligent drug discovery. CPU faculty and students can now log into the XtalPi AI drug discovery platform using campus network accounts to explore the powerful features of the initial AI toolkit, including PatSight and MolValley modules.
The deployment of XtalPi’s AI platform at CPU is a pivotal step in advancing intelligent pharmaceutical sciences. The university will leverage this opportunity to deepen collaboration with XtalPi in talent development and scientific research, fostering interdisciplinary integration. This initiative aims to cultivate a new generation of versatile pharmaceutical talent equipped for modern demands, produce innovative research outcomes, and drive the transformation of China’s pharmaceutical industry toward greater intelligence and efficiency.
XtalPi has long maintained close ties with universities, fostering collaborations in research exchange, technology transfer, and interdisciplinary talent development. By integrating its deep expertise in drug discovery with cutting-edge AI and robotic experimentation, XtalPi bridges biology, physics, chemistry, and pharmaceutical sciences to enhance scientific innovation and accelerate pharmaceutical industry advancements. This groundbreaking partnership with CPU represents a bold step in intelligent pharmaceutical education, aiming to deepen the application of advanced technologies in the field. Through sustained efforts, both parties seek to provide replicable models for intelligent drug discovery and address global challenges in pharmaceutical R&D.
